Culichi 🇲🇽 / Hematology & IM @incmnszmx / Leukemia
Distrito Federal, México
Joined July 2009
- Tweets32.2K
- Following937
- Followers1.1K
- Likes2.9K
Fausto A. Rios Olais retweeted
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: nej.md/4dBfwOk
Editorial: Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia nej.md/3UWmKWP
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia." The graph shows event-free survival. The trial name, AIEOP-BFM ALL 2017, is in parentheses after the title. The NEJM identity sits at the bottom.
🚨🚨🚨
In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: nej.md/4zJr1wV
Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML nej.md/4cgnBHO
ALT Shown are Kaplan–Meier curves for event-free survival (Panel A) and overall survival (Panel B) in the azacitidine–venetoclax and induction chemotherapy groups.
Fausto A. Rios Olais retweeted
📣 Sesión Académica Extraordinaria: “Leucemia linfoblástica aguda Ph+: estrategias terapéuticas contemporáneas y decisiones críticas”
👨⚕️ Ponentes:
Dr. Fausto A. Ríos Oláis 🇲🇽
Dr. Rubén Solís Armenta 🇲🇽
📅 Miércoles 12 de agosto de 2026
⏰ 19:00 h
🔗 sesiones-ameh.com/
Fausto A. Rios Olais retweeted
Muy honrados y orgullosos de recibir la certificación de ICOS @ICOSociety Centro de Excelencia en Cardioonco nivel Gold! Segundo centro en 🇲🇽 Gracias a todo el equipo! @incmnszmx @INCMNSZ_Ensena ! @CardiooncoINNSZ @ImagenCardiaca 💪🏼🥰❤️🐅@faustor @RobertaDemiche3 @ESCardioOnco 😇
Fausto A. Rios Olais retweeted
Proud to share our new piece in Blood Global Hematology, written with wonderful colleagues: @RobertaDemiche3 @castro_mollo @XimeJordan
"Hispanic/Latino" was built for policy, not biology. In leukemia, treating it as one group hides real diversity in ancestry, access & disease.
Rethinking Hispanic/Latino as an ethnic category in leukemia research ashpublications.org/bloodglo…
Fausto A. Rios Olais retweeted
ASH Plenary - IV Iron safe in infections! meetings-api.hematology.org/…
📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies?
In our @BloodAdvances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited.
@THilalMD
ashpublications.org/bloodadv…
Fausto A. Rios Olais retweeted
🎯 Bottom line:
Allo-HSCT offers curative potential in MDS/MPN overlap neoplasms.
PTCy (± ATG) appears to improve survival outcomes without added relapse risk.
👉 Further multicenter studies needed.
📖 Full study: doi.org/10.1111/ejh.14430
#HemeTwitter #AlloHSCT #GVHD
Fausto A. Rios Olais retweeted
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.
Read the full review “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress” by Robin Foà, MD, from @sapienzaroma: nej.md/4mhBDvU
ALT Review Article Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress Robin Foà, M.D. Figure 1. Timeline for Studies of Frontline TKIs plus Intensive or Lower-Dose Chemotherapy in Adults with Ph-Positive ALL, 1997–2024.
Fausto A. Rios Olais retweeted
Thanks to all the professors and attendees who joined us at this first hematology congress at @incmnszmx @DrWendyStock @garciamanero @PratzKW @AlejandroLazo2 @RubenNiesvizky @GCC_Cortes @EnriqueSoto8 @CarmeloGurnari @Meyaix @patsnavarrete @VazyurVasquez @rajuan_27
📢 Body composition in adult ALL
📊 In our study published at @ESPENorg, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections.
clinicalnutritionespen.com/a…
@RobertaDemiche3 @FernandoGLMD @analymorac @JessicaZaS
Fausto A. Rios Olais retweeted
🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉
Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario.
🔗 docs.google.com/forms/d/e/1F…
Tu aporte será clave para mejorar la atención de LLA en la región.
